All In Biotech

NDA 202192 · Incyte Corp

Jakafi

Ruxolitinib Phosphate · Oral · Kinase Inhibitor; Janus Kinase Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Nov 16, 2011

Approved uses

9

Original approval plus efficacy supplements

Registered trials

453

74 Phase 3, 109 recruiting

FAERS reports

68,626

34,968 serious, 9,975 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ( 1.1 ) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ( 1.2 ) steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ( 1.3 ) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. ( 1.4 ) 1.1 Myelofibrosis JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults. 1.2 Polycythemia Vera JAKAFI/JAKAFI XR is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea. 1.3 Acute Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older. 1.4 Chronic Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Mechanism: Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2, which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation, and subsequent localization of STATs to the nucleus leading to modulation of gene expression. MF and PV are myeloproliferative neoplasms (MPNs) known to be associated with dysregulated JAK1 and JAK2 signaling. In a mouse model of...

Therapeutic areas: Oncology · Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2022 Supplement 27 · Efficacy · priority review OrphanLabelLetter
  • Sep 22, 2021 Supplement 23 · Efficacy · priority review OrphanLabelLetter
  • May 24, 2019 Supplement 17 · Efficacy · priority review OrphanLabelLetterReview
  • Oct 10, 2017 Supplement 14 · Efficacy OrphanLabelLetterReview
  • Mar 10, 2016 Supplement 12 · Efficacy OrphanLetterLabel
  • Dec 4, 2014 Supplement 8 · Efficacy · priority review OrphanLabelLetter
  • Jul 25, 2014 Supplement 6 · Efficacy OrphanLabelLetter
  • Jun 12, 2013 Supplement 3 · Efficacy LetterLabel
  • Nov 16, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewLetterLabel
5 products under this application
  • JAKAFI · RUXOLITINIB PHOSPHATE EQ 25MG BASE · TABLET, ORAL · Prescription
  • JAKAFI · RUXOLITINIB PHOSPHATE EQ 15MG BASE · TABLET, ORAL · Prescription
  • JAKAFI · RUXOLITINIB PHOSPHATE EQ 5MG BASE · TABLET, ORAL · Prescription
  • JAKAFI · RUXOLITINIB PHOSPHATE EQ 20MG BASE · TABLET, ORAL · Prescription
  • JAKAFI · RUXOLITINIB PHOSPHATE EQ 10MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ruxolitinib" as an intervention, any sponsor and status, largest first.

All 453 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use14,354
  • death6,468
  • fatigue6,200
  • anaemia3,160
  • haemoglobin decreased2,999
  • platelet count decreased2,726
  • diarrhoea2,709
  • asthenia2,567
  • dizziness2,518
  • product dose omission issue2,480
  • headache2,393
  • pneumonia2,193

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2012483
2013839
20142,779
20152,509
20164,603
20174,335
20185,006
20195,210
20206,094
20216,475
20226,434
20236,566
20246,205
20256,136
20264,952

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jakafi (Ruxolitinib Phosphate)

2024 spending

$2.08B

Beneficiaries

15,713

130,891 claims

Per beneficiary

$132,549

$283.65 per unit

View as table
YearSpending
2020$1,296,674,522
2021$1,491,163,521
2022$1,756,404,369
2023$1,940,765,069
2024$2,082,741,189

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 398 on PubMed

Sponsor: Incyte

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.